Does delay in review of newly-diagnosed idiopathic pulmonary fibrosis (IPF) worsen outcomes?

H. Wu (Lancaster, United Kingdom), J. Wingfield-Digby (Lancaster, United Kingdom), T. Gatheral (Lancaster, United Kingdom)

Source: International Congress 2018 – News on the diagnosis of idiopathic interstitial pneumonia
Session: News on the diagnosis of idiopathic interstitial pneumonia
Session type: Thematic Poster
Number: 2934
Disease area: Interstitial lung diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
H. Wu (Lancaster, United Kingdom), J. Wingfield-Digby (Lancaster, United Kingdom), T. Gatheral (Lancaster, United Kingdom). Does delay in review of newly-diagnosed idiopathic pulmonary fibrosis (IPF) worsen outcomes?. 2934

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Effect of metformin on clinically relevant outcomes in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – ILDs: clinical aspects
Year: 2017


Are there differences in response to pulmonary rehabilitation (PR) in idiopathic pulmonary fibrosis (IPF) and COPD patients?
Source: International Congress 2017 – New insights into pulmonary rehabilitation in patients with chronic lung diseases
Year: 2017

Patient journey to diagnosis of idiopathic pulmonary fibrosis (IPF) in the US
Source: International Congress 2017 – ILDs: clinical aspects
Year: 2017


Can clinical data predict rapid decline of lung function in idiopathic pulmonary fibrosis (IPF) patients?
Source: International Congress 2017 – IPF: from the bench to the bedside
Year: 2017

Osteoporosis treatment effectiveness in patient with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012


Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF treatment II
Year: 2016


Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015

Warfarin and survival in people with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2007; 30: Suppl. 51, 246s
Year: 2007

Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence?
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015


Predictors of objective cough in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis
Year: 2019

Vulnerability of fatal infection under steroid treatment in patients with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2002; 20: Suppl. 38, 354s
Year: 2002

Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment
Source: International Congress 2016 – IPF treatment I
Year: 2016


Clinical course of idiopathic pulmonary fibrosis (IPF): Prediction and outcome
Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis?
Year: 2011

Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study
Source: Eur Respir J 2012; 40: 101-109
Year: 2012



Clinical burden of idiopathic pulmonary fibrosis (IPF): physician and patient perception
Source: Virtual Congress 2020 – Clinical aspects of idiopathic pulmonary fibrosis
Year: 2020


Is the severity of oxidative stress different in patients with end stage chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) waiting for lung transplantation?
Source: Annual Congress 2007 - Pathophysiology and assessment of COPD
Year: 2007


Towards a better diagnosis of idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2010 - Idiopathic pulmonary fibrosis: present understandings and future directions
Year: 2010

Sarcopenia in idiopathic pulmonary fibrosis (IPF): Prevalence and response to pulmonary rehabilitation (PR)
Source: Virtual Congress 2020 – Optimising the benefits of pulmonary rehabilitation
Year: 2020

A cohort of patients with a progressive fibrosing phenotype of interstitial lung disease (PF-ILD) other than idiopathic pulmonary fibrosis (IPF): the PROGRESS study
Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more
Year: 2020


Analysis of baseline characteristics by emphysema extent in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – ILDs: clinical aspects
Year: 2017